Company intelligence / Profile preview
Oak Therapeutics
Lawrence, Kansas, United Statesoaktherapeutics.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Oak Therapeutics has completed a critical Phase I milestone under an NIH/NIAID SBIR contract demonstrating bioequivalence between its proprietary isoniazid oral dissolvable strip and commercial tablets. The technology enables high-dose drug loading (>300mg), rapid dissolution (<1 minute), mucoadhesion, taste masking, and improved patient adherence—especially in children. The company is pursuing further clinical development and manufacturing scale-up.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Oral Thin Film/Oral Dissolvable Strip technology for small molecules and potentially biologicsSmall molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
NIH/NIAID SBIR program fundingcollaborations with University of Kansas faculty via KU Innovation Park incubator
Beyond the preview
Go deeper on Oak Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oak Therapeutics.